Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.44 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.44 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SLC1A5 | Q15758 | 2/20 | 0.41 |
| ▸ | KIF11 | P52732 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25413647 | 1.00 | ALDH1A1 (0.47) | ALDH1A1EHMT2EHMT1APOBEC3GHDAC1 | |
| SCHEMBL1498316 | 0.85 | EHMT2 (0.47) | ALDH1A1EHMT2EHMT1APOBEC3GMAPT | |
| SCHEMBL1498318 | 0.85 | EHMT2 (0.47) | ALDH1A1EHMT2EHMT1APOBEC3GMAPT | |
| SCHEMBL10086909 | 0.83 | ALDH1A1 (0.47) | ALDH1A1EHMT2EHMT1APOBEC3GHDAC1 | |
| Dipyridyl SCHEMBL5700787 | 0.81 | SLC1A5 (0.44) | ALDH1A1MAPTKMT2ASLC1A5KIF11 | |
| SCHEMBL19188184 | 0.81 | HDAC1 (0.47) | ALDH1A1EHMT2EHMT1APOBEC3GHDAC1 | |
| SCHEMBL4349165 | 0.80 | ALDH1A1 (0.43) | ALDH1A1EHMT2EHMT1APOBEC3GHDAC1 | |
| SCHEMBL1120030 | 0.80 | ALDH1A1 (0.43) | ALDH1A1EHMT2EHMT1APOBEC3GHDAC1 | |
| SCHEMBL31005446 | 0.80 | ALDH1A1 (0.43) | ALDH1A1EHMT2EHMT1APOBEC3GHDAC1 | |
| SCHEMBL1120092 | 0.80 | ALDH1A1 (0.43) | ALDH1A1EHMT2EHMT1APOBEC3GHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260053939-A1 | Combination Therapy for Cancer | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2026-02-26 | — | — | US | disclosed |
| EP-4469484-A1 | COMBINATION THERAPY FOR CANCER | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023159176-A1 | COMBINATION THERAPY FOR B-CELL DISORDERS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023144702-A1 | COMBINATION THERAPY FOR CANCER | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260053939-A1 | Combination Therapy for Cancer | BCL6, PSMB6, PDCD6 | ALDH1A1 4650/4885EHMT2 2009/4885EHMT1 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.